practrtioner skilled in ophthalmoscopy and many will require ophthalmological referral with slit lamp examination.
We suggest that the most cost effective and efficient screening programme is retinal photography as a first screening test. All patients with background or sight threatening retinopathy on photographs (280 of2014 = 14% in our data (table 1)) and all with poor quality films (162 of 2014 =8%) should then be reviewed by a trained professional using the ophthalmoscope (optician, trained general practitioner, or hospital specialist). This system will miss background retinopathy in 7.2% (108 of 1501) of patients on the primary screen, but sight threatening retinopathy in only 0.1 % (one of 1501). Repeat annual screening should pick up those background retinopathies that go on to progression of clinical significance and may well pick up at a further screen the minimal cases of sight threatening retinopathy that escaped primary screening. For health care systems with limited resources in terms of professional expenditure or limited access to these resources, this pragmatic approach to screening for diabetic retinopathy would be safe, efficient, and the most cost effective. There is a clear conceptual difference between screening for a risk factor of a medical condition and screening for the condition itself. If the same terminology is used for both, as suggested by Dr Haddow, this results in a loss of precision. For example, preconceptional "carrier screening for cystic fibrosis" is different from antenatal and neonatal "screening for cystic fibrosis". Preconceptional screening identifies individuals or couples who are carriers of the cystic fibrosis trait, a risk factor for having a child with the disease. In contrast, antenatal and neonatal screening can detect the condition, either in the fetus or in the newborn. However, antenatal screening includes the identification of parental carrier status before the detection of the condition in the fetus; therefore, when only the first part of the screening process is referred to, "carrier screening" is the logical term. Haddow's motive for abandoning the term "carrier screening" is "to guide perception as to how efficacy of screening should be judged". Although his call for the need to measure the efficacy of screening programmes can only be applauded, his editorial might cause some confusion about the appropriate measures needed to accomplish this task.
Measures of efficacy should reflect the objectives of a screening programme. Preconceptional and antenatal screening for conditions such as cystic fibrosis primarily aims at giving couples reproductive choice over the outcome of their future or existing pregnancies, as currently no treatment alternative can be offered that alters the prognosis of an affected fetus diagnosed before birth. Reproductive choice goes beyond the "choice of several options to avoid an affected child", as suggested by Haddow, as it includes the option of accepting an affected child. In contrast, the main objective of neonatal screening is to reduce morbidity and mortality of the condition through early detection.
Haddow's proposal to use as the "correct yardstick of screening efficacy the extent to which morbidity and mortality of the medical condition can be reduced" is inappropriate for screening programmes where the main objective is to give couples reproductive choice. Abandoning the term "carrier screening" does not help to direct attention towards this objective.
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Author's reply
Dr Zeuner's letter offers me an opportunity to further clarify my view as to why it is important to abandon the term "carrier screening". Her argument in favour of preserving the term is based upon the need for screening programmes to provide information about reproductive choice, including acceptance of an affected child (in this case, a child with cystic fibrosis), as well as antenatal diagnosis and a termination of pregnancy. Evaluating screening efficacy, of course, does not exclude offering information and reproductive choice to all screened couples as individuals, but it does mean that a sufficient proportion of the couples who receive a positive screening result take action that they would not otherwise have taken. If all couples with positive screening results chose not to avoid the birth of an affected child, it would be difficult to justify screening. The term "carrier screening" carries with it the inappropriate implication that success can be judged simply by documenting the number of cystic fibrosis carriers detected and counselled. "Screening for cystic fibrosis" focuses attention on the medical disorder and thereby places emphasis on the need to express efficacy in terms of reduced morbidity and mortality from the disorder.
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